Merck & Co., Inc, Rahway, NJ, USA.
Vantage Research, Chennai, India.
Cancer Cell. 2023 Sep 11;41(9):1680-1688.e2. doi: 10.1016/j.ccell.2023.08.004.
While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified. Data from 799 patients with melanoma (n = 176), non-small cell lung cancer (NSCLC; n = 146), gastric cancer (GC; n = 87), head and neck squamous cell carcinoma (HNSCC; n = 112), clear-cell renal cell carcinoma (ccRCC; n = 51), and urothelial carcinoma (UC; n = 227) TBP were included. Patients had received pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1.1. A subset of patients displays a 30% reduction in the sum of lesion diameters in the post-progression period (melanoma 24.4%, NSCLC 11.6%, 12.6% GC, 8.9% HNSCC, 15.7% ccRCC, and 13.2% UC). Most patients show stable target lesion dynamics in the post-progression period (melanoma, 64.8%; NSCLC, 72.6%; GC, 69.0%, 75.9% HNSCC, 72.5% ccRCC, 75.3% UC). Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.
尽管许多患者接受了进展后治疗（TBP），但这些患者的临床获益程度和持续时间尚未完全量化。该数据来自 799 名黑色素瘤（n=176）、非小细胞肺癌（NSCLC；n=146）、胃癌（GC；n=87）、头颈部鳞状细胞癌（HNSCC；n=112）、透明细胞肾细胞癌（ccRCC；n=51）和尿路上皮癌（UC；n=227）患者。这些患者在接受 pembrolizumab 治疗时已确认存在疾病进展（RECIST v1.1）。在进展后阶段，有一部分患者表现出肿瘤直径总和减少 30%（黑色素瘤 24.4%、NSCLC 11.6%、GC 12.6%、HNSCC 8.9%、ccRCC 15.7%和 UC 13.2%）。大多数患者在进展后阶段显示出目标病灶稳定（黑色素瘤 64.8%、NSCLC 72.6%、GC 69.0%、HNSCC 75.9%、ccRCC 72.5%、UC 75.3%）。Pembrolizumab 在接受 RECIST v1.1 进展后治疗的患者中产生了有意义的疗效。
